SCHEMBL5115267

SCHEMBL5115267

Cc1csc2nc(-n3ccnc3C)nc(NCc3ccc4c(c3)OCO4)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
TSHR P16473 5/20 0.44
MAPT P10636 5/20 0.44
NPSR1 Q6W5P4 4/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
TP53 P04637 1/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PDE5A O76074 6/20 0.43
ESR1 P03372 1/20 0.41
KDM4E B2RXH2 3/20 0.40
PPP1CA P62136 2/20 0.40
HPGD P15428 2/20 0.40
USP2 O75604 1/20 0.40
ALOX15 P16050 1/20 0.40
POLB P06746 1/20 0.40
MAPK1 P28482 2/20 0.39
EGFR P00533 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5130143 0.95 CHRM4 (0.42) ALDH1A1TSHRMAPTNPSR1KMT2A
SCHEMBL5122226 0.91 BCDIN3D (0.39) ALDH1A1TSHRMAPTNPSR1KMT2A
SCHEMBL5121556 0.86 PDE5A (0.41) ALDH1A1TSHRMAPTNPSR1PDE5A
SCHEMBL5118016 0.85 NOS2 (0.52) ALDH1A1TSHRMAPTNPSR1KMT2A
SCHEMBL5780791 0.84 HTT (0.48) ALDH1A1TSHRMAPTNPSR1KMT2A
SCHEMBL5115005 0.84 CHRM4 (0.41) ALDH1A1TSHRMAPTNPSR1KMT2A
SCHEMBL5129101 0.84 ALDH1A1 (0.46) ALDH1A1TSHRMAPTNPSR1KMT2A
SCHEMBL5118406 0.83 ESR1 (0.48) ESR1CLK4
SCHEMBL7615358 0.83 PDE5A (0.44) ALDH1A1TSHRMAPTNPSR1KMT2A
SCHEMBL5118442 0.82 ESR1 (0.48) ALDH1A1NPSR1KMT2AMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed
EP-0920431-A1 THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 1999-06-09 EP disclosed
WO-1998006722-A1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 ALDH1A1 1055/4885TSHR 1050/4885MAPT 2997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.